Overall verdict
Buy
6.8/10
1-year performance
+23.09%
Score breakdown
Up 23.1% over 1 year, 72% of the 52-week range.
Strongest: Profitability 8.4/10. Weakest: Financial strength 4.0/10.
26 analysts, target +0.2% vs the price.
UnitedHealth Group Incorporated operates as a health care company in the United States and internationally. It operates through four segments: Optum Health, Optum Insight, Optum Rx; and UnitedHealthcare. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services with patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities.
The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, public entities, life sciences companies and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease and drug therapy management.
The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals ; Medicaid plans, including Temporary Assistance to Needy Families ; Children's Health Insurance Programs ; Dual SNPs ; Long-Term Services and Supports ; Aged, Blind and Disabled ; and other federal, state, and community health care programs. and health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. UnitedHealth Group Incorporated was founded in 1974 and is based in Eden Prairie, Minnesota.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Stephen Hemsley
Founded
1974
Employees
390 000
Revenue / employee
1.1M USD
Next earnings
January 12, 2027 (estimated)
Institutional holders
- FMR LLC3.47%
- GEODE CAPITAL MANAGEMENT, LLC2.32%
- Bank of New York Mellon Corp1.15%
- Rest of the register93.07%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
461.62 USD
52-week low
255.97 USD
1-year performance
23.09%
Rising
Year-to-date performance
22.18%
Rising
Drawdown
-12.42%
Mild pullback
Position in the 52-week range
72% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of December 2000 are worth today
| UnitedHealth Group | $348,598 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.8 times as much as the world ETF.
- Worst fall:-68 % between December 2005 and February 2009. $10,000 placed at the top fell to $3,168. The world ETF, at worst: -53 %. Back to its high in 50 months.
UnitedHealth Group earned 5 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- UnitedHealth Group: $348,598
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 413.10 USD - 428.58 USD (3 methods agree)
The price implies growth of 1.97% per year; the company grows at -3.76%.
Gross margin 88.3%, net margin 3.5%, ROIC 9.5%, ROE 16.4%.
Net margin
3.53%
Exceptional
Sector 0.76%|S&P 13.40%
Gross margin
88.31%
Exceptional
Return on equity (ROE)
16.39%
Exceptional
Sector 8.65%|S&P 17.06%
Return on invested capital (ROIC)
9.48%
Exceptional
Free cash flow margin (FCF)
5.08%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.44x
Fair
Margin stability
1.2 pts
Very steady
Revenue to net income
Growth
6.4/10Revenue down 0.4% over 1 year, 11.7% a year over 5, EPS -3.8% a year over 5.
Revenue (trailing 12 months)
450Md USD
Revenue growth (1y)
-0.41%
Declining
Revenue growth (3y)
38.07%
Solid
EPS growth (1y)
76.21%
Hyper-growth
EPS CAGR (5y)
-3.76%
Declining
EPS revisions (3 months)
3.57%
Revised up
Valuation
6.9/10P/E 23.1x, forward P/E 20.9x, EV/EBITDA 14.7x, PEG 0.30. The multiple sits in the 87th percentile of its own 5-year history.
P/E (TTM)
23.1x
Fair
Sector 35.3x|S&P 23.6x
Forward P/E
20.9x
Fair
EV / EBITDA
14.7x
Fair
Sector 18.5x|S&P 15.5x
PEG
0.30
Growth unpriced
Sector -0.20|S&P 0.91
Fair value (reverse DCF)
420.84 USD
Fairly priced
P/E vs its own 5-year history
among the 13% highest valuations
At its historical high
Market cap
362Md USD
Financial strength
4.0/10Cash covers 34.8% of the debt, net debt/EBITDA 1.8x.
Net debt / EBITDA
1.8x
Stretched
Gearing (net debt / equity)
45.94%
Solid
Cash
25.8Md USD
Cash / market cap
7.13%
Tight
Cash / total debt
34.77%
Solid
Interest coverage
6.2x
Solid
Net debt
48.5Md USD
Equity
106Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 405.12 USD
- MM20407.14
- MM50391.06
- MM200364.70
- RSI 1453.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.93%
200-day average slope, 3 months
+5.23%
50-day average slope, 1 month
+0.67%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
1.91 % per day
Volatility change
+26.02%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 19.36 (15) | 20.61 (25) | 449 048 (20) | 31 050 (12) | 17 475 (14) |
| 2027 | 21.89 (15) | 23.33 (26) | 462 929 (22) | 34 011 (12) | 20 134 (13) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.2 | 7.5 | 2.7Md USD | 33.5x | 6.8 % | 8.9 % | 17.8 % | -3.1x | 6.7 % | 53.4 % | ||
| 2 | HQY | 7.0 | 6.8 | 8.5Md USD | 37.2x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 5.7 % | 3.4 % | ||
| 3 | ELV | 6.8 | 6.7 | 92.8Md USD | 18.3x | 2.5 % | 1.4 % | 6.8 % | 3.0x | 7.0 % | 40.0 % | ||
| 4 | UNH | 6.8 | 6.7 | 362Md USD | 23.1x | 3.5 % | -0.4 % | 9.5 % | 1.8x | 6.3 % | 23.1 % | ||
| 5 | SAUD3 | 6.4 | 5.9 | 8.4Md USD | 16.8x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.5 % | 36.5 % | ||
| 6 | CNC | 5.8 | 5.8 | 34.9Md USD | 24.2x | 0.7 % | 1.9 % | 3.8 % | -1.4x | 11.3 % | 102.9 % | ||
| 7 | HUM | 4.9 | 3.5 | 53.6Md USD | 43.4x | 0.8 % | 26.1 % | 4.1 % | -2.2x | 5.9 % | 86.0 % | ||
| 8 | MOH | 4.7 | 2.8 | 10.9Md USD | Not meaningful (loss) | -0.1 % | -3.4 % | -0.6 % | -22.1x | 2.2 % | 47.1 % | ||
| 9 | CLOV | 4.3 | 1.9 | 2.6Md USD | 263.0x | 0.5 % | 52.9 % | — | — | — | 91.2 % |
